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Abstract 
 
As pharmacists move away from traditional dispensary roles and towards more clinical 
services, a therapeutic realm that pharmacists are exploring is travel medicine. However, travel 
medicine can be challenging to beginners in the field. Despite an expansion in scope in 
December 2016 allowing pharmacists in Ontario, Canada, to administer a broader range of 
vaccines including many indicated for travel, the uptake of these services by pharmacists has 
been slow. Key reasons include a lack of confidence in travel medicine knowledge and 
challenges integrating the service into existing workload.  
To assist with identifying patients who may be manageable by pharmacists without 
additional travel medicine training, versus those who may benefit from referral, we developed 
and validated a clinical practice framework. A panel of experts, comprised of physicians and 
pharmacists holding a Certificate in Travel HealthTM from the International Society of Travel 
Medicine, generated the initial content on information gathering and assessing risk in a travelling 
patient. The initial list of 114 items was then judged by the panel to remove non-essential items, 
resulting in 64 items proceeding to content validation, organized into 5 ‘W’ domains: Who, 
What, Where, When, and Why. Each item was ranked by the experts according to its relevancy, 
resulting in an Average Content Validity Index of 0.91. The resulting framework was titled “The 
5W Approach to Travel Risk Identification.” This clinical practice framework is the first 
published assessment tool for travel medicine tailored for pharmacy’s scope of practice that has 
been content validated. 
 The tool allows pharmacists inexperienced in travel medicine to collect information 
required to use their professional judgement when assessing travelling patients as either high-risk 
(requiring a referral to a travel medicine specialist) or low-risk. With the aim of supporting 
v 
 
pharmacists to be more confident in caring for travelling patients and increasing their 
involvement in travel medicine, this framework was then piloted in 8 pharmacies in Ontario, 
Canada, from March to August 2019. Pharmacists completed pre- and post-test phase surveys to 
determine the utility of the framework. Pharmacists reported that the framework is simple to use 
and provides structure for interactions with travelling patients. However, it may not be as 
beneficial for those with a higher level of travel medicine expertise than the average pharmacist, 
and improvements to its design were suggested. This feasibility study is the first to trial the use 
of a validated risk assessment framework for pharmacists to use when providing care to 
travelling patients. To further understand its potential in community pharmacies, this work will 
be further expanded to pharmacists across Canada.  
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Chapter 1: Introduction 
 
1.1 Travel Medicine 
 
Travel medicine is defined as “the field of medicine concerned with the promotion of 
health…for the peoples, cultures and environment of regions being visited in addition to the 
prevention of disease or other adverse health outcomes in the international traveller.”1 The 
terms “travel medicine” and “travel health” are often used interchangeably and refer to the 
same clinical speciality referenced previously. It is a unique therapeutic area requiring a 
high level of individualization for each traveller’s health needs and level of risk during 
travel. A travelling patient’s risk can vary depending on their trip itinerary and patient 
characteristics, and there is limited existing information regarding actual risk for travellers 
(often expressed as number of events per 100,000 travellers).2 Common health-related 
considerations within travel medicine include, but are not limited to: immunizations, 
travellers’ diarrhea, malaria chemoprophylaxis, and insect bite prevention. Rising rates of 
international tourism – projected to reach 2 billion arrivals annually by the year 2030 – 
coupled with increasing diversification of destination countries (for example, increasing 
travel to Asia, the Middle East, and Africa),2 are likely to make travel medicine 
consultations a service sought out by many patients. As a continually evolving and highly 
dynamic specialty, health professionals providing travel health services must be up-to-date 
on a variety of topics, including global epidemiology of infectious and non-infectious 
health risks, health regulations, and immunization requirements and recommendations.3  
1.1.1 Travel Medicine Body of Knowledge 
Clinical knowledge related to travel health is often self-acquired by those with a strong 
interest, mainly through learning activities such as workshops, online continuing education 
programs, and clinical readings. Most travel medicine practitioners gain their skillset 
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through practical experience in providing travel consultations. The largely self-taught 
avenue of learning may be attributed to the fact that travel medicine is not a core 
component of many healthcare professional schools across Canada and the United States.4-6 
The majority of travel medicine courses are offered to postgraduates or licensed 
professionals, as opposed to students or trainees.7-9 
The organization central to travel medicine practice for healthcare professionals – 
the International Society of Travel Medicine (ISTM) – advises that at least 3 years of travel 
medicine experience is recommended in order to gain the body of knowledge required for 
their Certificate in Travel HealthTM (CTH®) examination.10 The breakdown of the 
examination content can be found in Appendix A. 
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1.2 Pharmacy Practice & Travel Medicine 
 
Pharmacist involvement with the delivery of travel health services is a relatively new but 
developing field. Community pharmacists have always been available to help travelling 
patients by recommending products for minor ailments (e.g., motion sickness, mosquito 
bite prevention) and dispensing medications when needed for travel (e.g., malaria 
chemoprophylaxis, antibiotics for travellers’ diarrhea). However, offering comprehensive 
travel health services including pretravel consultations and vaccinations has been only been 
recently adopted by pharmacists. Despite its infancy, its uptake has been seen both in 
Canada and internationally, particularly among pharmacists in developed countries, as 
evidenced by the creation of a Pharmacist Professional Interest Group within the ISTM.11 
1.2.1 Canadian Pharmacist Scope of Practice & Travel Medicine 
Pharmacy practice in Canada is evolving, as pharmacists are stepping out of their 
traditional dispensary-based role and positioning themselves as key players in a patient’s 
circle of care. Depending on provincial legislation as indicated in Figure 1, pharmacists 
may be able to perform more clinical patient care duties including prescribing, 
administering drugs and vaccines by injection, assessing and treating minor ailments, and 
ordering and interpreting laboratory tests, among others.12 Pharmacists are a frequent first 
point of contact with the healthcare system for many patients. It is not unusual for a request 
of advice on the selection of a non-prescription product to result in the identification of a 
sign or symptom that requires further assessment or referral to another primary care 
professional. This is expected to also be the case with travellers, who may request advice on 
sunscreen, or present with a prescription for an antibiotic for the treatment of traveller’s 
diarrhea without having received a comprehensive evaluation of their travel health risks. 
With a recent scope expansion in December 2016 allowing Ontario pharmacists to 
administer a number of vaccines commonly used for travel,13 pharmacists can expect to 
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encounter more opportunities to identify patients who would benefit from a comprehensive 
pre-travel consultation. Evidence has found that only a small proportion of individuals who 
are travelling receive a pre-travel consultation to consider their individual health risks.14,15 
As the most accessible healthcare professional, with flexible hours of operation, and broad 
geographic distribution including rural communities that may not have a specialized travel 
clinic, this convenient access to travel advice is expected to positively impact the 
proportion of travellers who can access this care.  
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Figure 1 – Summary of Pharmacists’ Scope of Practice in Canada12 
 
As seen in Figure 1, there is a wide provincial/territorial variation in the extent of 
travel health care that can be provided by a pharmacist. Furthermore, jurisdictional 
differences also exist regarding which patients may qualify to receive certain services from 
pharmacists (e.g., minimum age for immunization), access to patient’s health records, and 
remuneration for services.12 For example, in Alberta, pharmacists that have met the 
requirements for Additional Prescribing Authorization can independently prescribe any 
vaccines or medications used for travel.16 Pharmacists with at least 1 year of clinical 
experience can apply; the application includes describing their practice, preparedness, and 
judgment and submitting 3 actual patient cases within the past 2 years which is then 
reviewed by at least 2 pharmacists against activities and indicators such as patient 
assessment, developing a care-plan and following up, collaboration, and documentation.16 
However, legislation in other provinces is not as broad. In Manitoba, pharmacists have the 
option to apply to be an Extended Practice Pharmacist as long as the applicant has their 
CTH® and ≥ 1000 hours of experience.17 Once approved, the pharmacist can prescribe 
drugs or vaccines “within the scope of their specialty practice.”17 Extended Practice 
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Pharmacists must meet the condition of having a collaborative practice with a medical 
doctor, nurse practitioner, or a registered nurse with Extended Practice designation, which 
involves the two parties having mutual patients, acknowledging shared risk and 
responsibilities in the care of the patient(s), and having immediate access to the patient’s 
diagnostic and health information.17 In New Brunswick, the legislation is divided based on 
pharmacists with and without their CTH®.18,19 Any pharmacist, regardless of CTH® status, 
can prescribe for “preventable disease” including vaccines for cholera, hepatitis, measles, 
mumps, and rubella, and drugs for malaria and travellers’ diarrhea.18 However, pharmacists 
with CTH® have additional prescribing authority for vaccines against rabies, typhoid, 
Japanese encephalitis, and yellow fever.19 However, a gap exists with this legislation as 
pharmacists are limited in their prescribing to specific travel health conditions, being unable 
to prescribe for common ailments and prevention of other conditions such as altitude illness 
or doxycycline for leptospirosis.  
1.2.2 Ontario Pharmacy Practice and Travel Medicine 
Ontario pharmacists have been authorized as immunizers against influenza for patients aged 
5 years and older since 2012. This authorization is contingent on successful completion of 
an immunization training program and obtaining a valid certification in cardiopulmonary 
resuscitation and first aid.20 In December 2016, pharmacists’ scope was expanded to 
include authority to immunize against 13 additional vaccine-preventable diseases. Many of 
the vaccines included are travel-related (Table 2). While pharmacists have the authority to 
immunize, the caveat is that the majority of the vaccines that are allowed to be administered 
by pharmacists must first be prescribed, and pharmacists in Ontario currently only have 
prescribing rights for medications involved in smoking cessation.21 Vaccinations that do not 
require a prescription are limited to those involved in Ontario’s routine immunization 
schedule.  
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Table 1 – Vaccines authorized to be administered by an injection-certified pharmacist in 
Ontario22 
Vaccine Prescription Required 
Bacillus Calmette-Guerin Yes 
Haemophilus influenzae type B No 
Meningococcal No 
Pneumococcal No 
Typhoid Yes 
Typhoid/Hepatitis A Combination Yes 
Hepatitis A Yes 
Hepatitis B Yes 
Hepatitis A&B Combination Yes 
Herpes zoster Yes 
Human papillomavirus No 
Japanese Encephalitis Yes 
Rabies Yes 
Varicella Yes 
Yellow Fever Yes 
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1.3 Clinical Practice Frameworks 
 
Pharmacists currently utilize various frameworks to guide patient assessments across a 
number of therapeutic areas. These frameworks are especially helpful to those new to these 
services such as students and new practitioners; however, even experienced clinicians 
continue to refer to these to ensure a consistent approach to their patient assessments and 
documentation. For example, assessments related to patient self-care of common ailments 
often follow the “SCHOLAR” (Symptoms, Characteristics, History, Onset, Location, 
Aggravating factors, Remitting factors) and “MACS” (Medications, Allergies, Conditions, 
Social history) mnemonics.23 Similarly, the “OPQRST” (Onset, Palliation and provocation, 
Quality and quantity, Region and radiation, Signs and symptoms, Temporal relationship) 
mnemonic is valuable to the assessment of pain.24 These frameworks provide health 
professionals with a structure to perform these assessments upon, adding to their 
confidence that their assessment will not miss any important elements that may affect their 
clinical decision-making.  
A review of the literature in PubMed, using search terms “travel medicine,” “risk 
assessment,” and “triage,” did not identify any published triaging tools or frameworks 
available to assist healthcare professionals with both information gathering and clinical 
decision making when performing pre-travel consultations. While a number of clinical 
practice guidelines3,25,26 and publications such as the Centers for Disease Control and 
Prevention’s (CDC) Yellow Book: Health Information for Travelers exist, little guidance is 
provided on how to interpret and implement this information into practice. This results in a 
wide variation of treatment experiences and recommendations for the travelling patient and 
inconsistencies in the assessment of a travelling patient’s healthcare needs. 
As previously mentioned, there are many articles reviewing the therapeutics of 
travel medicine for both pharmacists and physicians. In both the American Family 
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Physician and Canadian Family Physician journals, review articles were published that 
detail how to conduct a pretravel consultation.3,26 Information is presented on immunization 
and travel-related conditions, but the key component missing is how to ascertain and 
manage a travelling patient’s individual risks. Although the Canadian Family Physician 
article does provide a travel medicine triage algorithm and sample pretravel risk assessment 
questionnaire,3 its use in practice is uncertain as it has not been tested for validity, 
comprehensiveness, and feasibility. Moreover, its applicability to pharmacists in the 
community setting is uncertain due to differences in practice sites, scope of practice, and 
approach to patient assessments from those used by family physicians who are the intended 
audience of the article. 
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1.4 Pharmacists’ Interventions in Travel Medicine 
 
A review of the known literature regarding pharmacists’ interventions on travel-related 
health conditions yields few results. Most articles are comprised of reviews detailing the 
therapeutics of travel medicine for pharmacists (e.g., treatment of travellers’ diarrhea, 
malaria chemoprophylaxis). Few studies explore the health outcomes of pharmacist care 
towards travelling patients or pharmacists’ competence in travel medicine. Of the known 
literature, the research results surrounding pharmacists’ interventions related to travel 
medicine can be categorized into two themes: 
1. Given extensive postgraduate training and experience in practice, pharmacists 
can positively impact health outcomes among travellers.27-31 
2. Given the minimal competencies required for pharmacists to practice, 
pharmacists are inadequately prepared to care for travelling patients. Further 
education and training regarding travel medicine for pharmacists are also often 
discussed in the studies within this theme.32-34 
1.4.1 Pharmacists with Travel Medicine Expertise 
Pharmacists whose travel-related care has been studied can simply be divided into two 
types: those with or without travel medicine expertise. This expertise is often defined as 
individuals with CTH® designation, and/or those who have completed a post-baccalaureate 
Doctor of Pharmacy (PharmD) with or without a hospital-based or primary care residency. 
These pharmacists who have travel medicine experience appear confident in their care, as 
exhibited through creating their own travel health clinics, and demonstrate strong patient 
outcomes and pharmacist competence. Durham et al., demonstrated that pharmacists 
provided more consistent evidence-based care concordant with guideline recommendations 
when comparing pharmacist travel health specialists versus primary care providers with no 
travel health expertise.27 Specifically, antibiotics for the prevention and treatment of 
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travellers’ diarrhea, malaria chemoprophylaxis, and immunizations against vaccine-
preventable diseases were prescribed more appropriately under pharmacist travel health 
care than primary care.27 Primary care providers were more inconsistent with the 
guidelines, defined as either ordered a drug when not indicated (e.g. 21% vs. 3% for 
travellers’ diarrhea, p <0.0001) or did not order a drug when indicated (e.g. 49% vs. 6% for 
travellers’ diarrhea, p < 0.0001).27 Patient receipt of recommended vaccinations was also 
higher among patients cared for by the travel health pharmacists (mean= 2.77 vs. 2.31, 
p=0.0039).27 Furthermore, a study of a telepharmacy travel clinic estimated a saving of 
$47,000 annually (based on ~720 consults) in unnecessary vaccinations when compared to 
a nurse-based travel clinic, such as vaccinations for travel to countries with a low risk for 
travel-related vaccine preventable disease, or for patients with itineraries that place them at 
low risk of exposure.30 However, the generalization of these savings is potentially limited 
due to the fact that the study focussed on a single site - the Clinical Pharmacy International 
Travel Clinic serving the Kaiser Permanente Colorado Region. The cost-analysis of 
pharmacist interventions on travel medicine have not been extensively studied and no 
definitive recommendations for its implications can currently be made.  
Studies have also demonstrated a high level of patient satisfaction and acceptance of 
recommendations made by a pharmacist with CTH® designation. A retrospective cross-
sectional study by Tran et al. found that pharmacist recommendations in a pretravel 
supermarket pharmacy clinic were well accepted, including a 79.4% acceptance rate for 
hepatitis A vaccine.31 Overall satisfaction was rated at 94% for the pharmacist-provided 
travel clinic. Tran et al.’s results correlate closely with Hess et al.’s high patient acceptance 
rates of their comprehensive pre-travel health clinic.28,31 Notably, both studies have practice 
settings that reflect those of Canadian community pharmacies, as opposed to primary care 
clinics where pharmacists operate under medical directives in other studies. A recent 
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Canadian cohort study conducted in Alberta, a province where pharmacists have been 
practicing with broad scopes related to administering immunizations and prescribing for a 
more extensive period than Ontario, provides further evidence supporting the role of 
pharmacists in travel medicine. Of a convenience sample of patients presenting to a 
pharmacist-managed travel clinic, positive patient satisfaction and health status while 
travelling was found, with 94% of participating patients reporting being either very 
satisfied or satisfied with the care delivered, with infrequent health concerns occurring 
during travel.29 Among patients who did have a health concern while travelling, 93% felt 
adequately prepared by the pharmacist to manage the condition.29  
1.4.2 Pharmacists without Travel Medicine Expertise 
However, the literature has identified areas for improvement when evaluating care provided 
by pharmacists without additional travel medicine training.32-35 In a pilot study examining 
pharmacist-provided education and adherence rates for the oral typhoid vaccine, 59% of 
travellers did not report having received any verbal education from the dispensing 
pharmacies.32 Furthermore, while 80% of travellers received written material from the 
pharmacy, such as product monographs or patient education sheets, only 37% of patients 
found this information helpful.32 Although this hospital-based clinic located in rural 
Colorado, named the Traveler’s Clinic, states that patients were given education in both 
written and oral formats during their visit, the study’s findings are limited by potential 
recall bias, as data was collected through a retrospective telephone survey where travellers 
were contacted within 6 months of receiving their prescription.32 Nonetheless, because the 
vaccine has a unique dosing schedule and subsequent compliance issues, appropriate 
measures should be undertaken, such as follow-up strategies, to ensure travellers have 
received and understood its education and instructions for use.32 Even when pharmacists 
self-identified as experienced travel health advisors (although not supported by ISTM’s 
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CTH® designation), their recommendations for rabies pre- and post-exposure prophylaxis 
were generally discordant with guidelines.33 Ross et al., demonstrated that travel medicine 
topics such as rabies pre- and post-exposure prophylaxis can exhibit flaws even with an 
“experienced” group of healthcare professionals,33 highlighting the need for a standardized 
approach to travel medicine patient cases that will be discussed further. The assessment of 
answers from their internet-based questionnaire scenarios found that the participants do not 
inform travellers equally about the risk of rabies in countries where the disease in enzootic, 
with only 35-60% of the advisors providing this information to those planning business 
trips, packaged tours, or travel to urban centres.33 It is important to note that this data 
includes both pharmacists and physicians and no specific analysis was done to single out 
pharmacist care. Lastly, in a questionnaire by Teodosio et al. surveying Portugal 
pharmacists’ travel advice for the tropics, many responses contained incomplete and/or 
incorrect travel advice.34 For example, when asked to identify which Portuguese-speaking 
countries warrant yellow fever vaccination, only 8 out of 91 pharmacists (8.8%) could 
correctly do so.34 However it is interesting that pharmacists’ personal interest in travel 
medicine even without additional training appeared associated with more appropriate 
recommendations.34 In another telephone questionnaire of pharmacists in Switzerland by 
Kodkani et al., when spontaneously asked to provide advice on malaria protection for 
travellers to Thailand and Kenya only 19% and 31% of pharmacists gave accurate advice 
on those travel destinations, respectively.35 A similar trend can be exhibited in Canada, 
where many pharmacists have an interest in travel medicine but do not feel they are 
currently adequately prepared for such clinical scenarios.36 It is important to note that 
although pharmacists may not feel confident in providing travel health advice unaided, 
pharmacists are confident in knowing which sources to consult for travel health information 
if an answer needed to be looked up.36 This is notable as the accuracy of advice in Kodkani 
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et al.’s study increased when pharmacists were allowed to consult their resources, 
particularly for malaria prevention with accuracy rates of 74% for Thailand and 93% for 
Kenya.35 
A sub-theme relating to pharmacists’ preparedness when caring for travelling 
patients is the need for further training or education in travel medicine. Due to travel 
medicine’s complexity, need for individualized care, and unfamiliarity to the average 
pharmacist, this lack of education could be a key barrier stopping pharmacists from 
providing even basic travel medicine services. Many preliminary studies have identified 
this barrier, and suggest that a gap in training in pharmacy school curricula is a 
contributor.4-6,36 Pharmacy schools across the US and Canada do not have robust travel 
medicine competencies built into their core curricula, apart from immunization training, 
which tends to focus on influenza vaccination.4-6,36 This lack of exposure during 
pharmacists’ training years as students likely impacts the provision of these services upon 
licensure. Further investigations into the scope of this problem need to be completed in 
order to make a definitive conclusion. 
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1.5 Current Landscape and Associated Challenges of Travel 
Medicine Scope for Ontario Pharmacists 
 
As previously mentioned, in December 2016 the Ontario government expanded the scope 
of pharmacists’ immunizations to include 13 vaccine-preventable diseases in addition to the 
influenza vaccine.21 The focus of these vaccines is largely travel-related. Although 
expansions in scope are generally well-received, legislative changes do not directly result in 
practice changes. As observed with previous expansions to scope (e.g. adapting and 
renewing prescriptions or conducting medication reviews), pharmacist uptake of new roles 
and responsibilities can be a gradual process and there may be hesitation to implement it 
into practice.37-40 A number of practical factors such as increased workload, patient safety 
concerns, and complexity of the clinical area coming into scope can make pharmacists 
hesitant to change.41  Additionally, questions can linger on how employers will support 
pharmacists in a new scope of practice or whether or not decision makers have taken into 
account the infrastructure, remuneration, or workflow considerations unique to the 
pharmacy profession.41 This culture of slow pharmacy practice change can also be linked to 
pharmacists’ personality traits related to patient care, including: lack of confidence, fear of 
new responsibility, paralysis in the face of ambiguity, need for approval, and risk 
aversion.42 The traditional scientific nature of the profession and its education emphasizing 
memory and adherence to procedures, as opposed to application of knowledge and clinical 
judgment, leading pharmacists to not take action until their arguments or conclusions are 
fully solidified.43  
1.5.1 Ontario’s Uptake of Expanded Immunization Services 
In an online survey released 1-2 years after the expansion of Ontario pharmacists’ scope, 
input from 205 pharmacist respondents was gathered to understand how the change in 
scope was being used among Ontario pharmacists. Following the online survey, telephone 
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interviews were conducted with 6 participants until saturation was reached. The results are 
as follows: 
1.5.1.1 Vaccination 
87% (n=178) of respondents were injection-certified by the college and, of these, 78% 
reported personally administering travel vaccines at their pharmacy (defined as any 
vaccines currently within their scope other than influenza).44 Vaccination was most 
commonly performed by walk-in (69%), followed by appointment (24%) and during set 
days or hours such as a clinic day (6%). However, the preferred method by 54% of 
respondents was appointment-based, with 17% preferring walk-in.44 Figure 2 illustrates the 
self-reported breakdown of vaccines administered since the expansion of scope. 94% of 
respondents reported administering fewer than 10 of these vaccines per month in total, 
indicating a slow uptake of this service.44 It is important to note that this number can also 
include non-travel vaccines, such as herpes zoster and human papillomavirus.  
Figure 2 – Self-report of vaccinations administered by pharmacists since scope expansion 
in December 201644 
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1.5.1.2 Pretravel Consultations 
Pre-travel consultations were offered by roughly 1 in 4 respondents (n=56, 27%).44 Similar 
to vaccination administration, consultations were most commonly done via walk-in (55%), 
followed by appointment-based (40%). Again, pharmacists preferred to do consultations via 
appointment (62%), with only 16% preferring walk-in.44 Aside from vaccination, pretravel 
consultations were the most frequent service offered, and had a relative increase in 
frequency of 33% two years following scope expansion versus before (see Figure 3).44 
Patients requiring travel advice and/or vaccinations were identified in one of three ways: 1. 
Patients self-identifying (e.g. patient presents to pharmacy asking what vaccinations are 
needed for an upcoming trip); 2. Referral from other healthcare professionals who were 
aware of the pharmacists’ scope; 3. Pharmacists’ identification based on incoming 
prescriptions related to travel (e.g. travellers’ diarrhea, malaria chemoprophylaxis).44 In 
terms of future thinking, “71% of respondents indicated an interest in receiving their 
Certificate in Travel Health® designation from the International Society of Travel Medicine 
within the next 5 years.”44 
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Figure 3 – Travel related services offered by pharmacists pre- and post- scope expansion44 
 
Asterisk denotes activity requiring delegation or medical direction. 
1.5.1.3 Confidence with New Scope 
While pharmacists are highly confident in immunization against influenza, varying 
confidence levels were found with the additional vaccinations added to their scope.  
Confidence levels could be attributed to:44 
• “Lower demand for non-influenza vaccinations:”44 In Ontario, there is a universal 
influenza immunization campaign, with vaccination recommended for all residents 
without contraindications to the vaccine. However, the other vaccines do not have 
such universal recommendations resulting in less indications and lower demand to 
be vaccinated.  
• “Confidence is directly related to level of exposure:”44 The lower demand meant 
less opportunities for pharmacists to administer the additional vaccinations and 
determining their clinical appropriateness. One pharmacist that had been practicing 
with a medical directive to administer non-influenza vaccinations since 2012 
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reported high confidence, which was not seen with the other respondents. Others 
had varying confidence depending on the vaccine (e.g. more confidence with herpes 
zoster than yellow fever). 
• “Duration of available scope:”44 Influenza vaccination by pharmacists has been 
authorized for a longer time than the new additional vaccinations (2012 vs. 2016). 
Time has allowed pharmacists to become more comfortable with all the parameters 
involved in vaccination against influenza (e.g., volume, route, adverse effects). 
However, pharmacists’ familiarity is not the same for the additional 13 vaccines 
because there hasn’t been a long enough duration of exposure to become 
comfortable with the knowledge associated with these additions to scope.  
1.5.1.4 Barriers and Facilitators 
Survey respondents cited a number of barriers and facilitators impacting uptake of these 
immunization services. As seen by Figures 4 and 5, respectively, more barriers were 
mentioned than facilitators. Education in travel medicine and prescribing authority were 
seen to be 2 factors that can most help with pharmacists’ uptake of this scope. In terms of 
travel health training, one pharmacist reported “[it’s] kind of like you need to go above and 
beyond what is out there to make sure you have the background information….it’s not like 
every day practice.”44 However, time to provide services, lack of training and lack of 
awareness of the new scope among the public were seen as the top barriers. As one 
pharmacist said, “I don’t think [regulation change] had a big change. I don’t know if the 
patients are even aware about it or if it’s advertised.”44 A strong facilitator mentioned 
across all pharmacists that were interviewed was the convenience that pharmacist-provided 
services offers for patients. As one pharmacist said “you can wait and go to your doctor, if 
you like, go book an appointment, take another day off work…Or you can get them right 
here, right now, and maybe wait for five minutes or ten minutes for me.”44 Despite this 
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positivity, uptake of these services is still deemed slow and receptiveness is not as open as 
other pharmacist activities (e.g., influenza immunization). 
Figure 4 – Barriers affecting pharmacist offering of travel-related services44 
 
Figure 5 – Facilitators (actual or potential) affecting pharmacist offering of travel-related 
services44 
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1.6 Aim and Scope of Thesis 
 
The aim of this thesis was to develop and test a clinical practice framework that can address 
the challenges pharmacists face when beginning to provide travel medicine services. Two 
phases of research were completed: 1) development, and 2) assessment of the framework. 
The development phase primarily consisted of a panel of CTH® experts creating a content-
validated tool. The assessment phase focussed on community pharmacists’ experiences 
using the framework from March to August 2019. 
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1.7 Significance of Thesis 
The aforementioned framework will be the first of its kind to be created in the clinical area 
of travel medicine. The anticipated significance is three-fold: 
a. Link travel medicine risk assessment into a practice-focused approach that 
has never been explored before among pharmacists. 
b. Address knowledge gaps regarding travel medicine risk assessments that 
may be preventing pharmacists from offering this clinical service, 
particularly for low-risk patients.  
c. Provide an efficient and accurate tool that pharmacists have identified as 
being a potential facilitator to their uptake and incorporation of travel 
medicine services,36,44 with consideration of existing pharmacy workflow.  
Currently, the framework will be developed for, and tested by, pharmacists. 
However, if successful, this framework can be trialed among other healthcare professions, 
such as medicine and nursing, for even broader adoption of travel medicine services into 
practice.  
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1.8 Thesis Overview 
 
This chapter has introduced the reader to the current landscape of travel health services 
among pharmacists, including its challenges, perceptions, benefits, and initial impact of the 
expanded scope of practice for Ontario pharmacists. The following two chapters will 
feature the two phases of the thesis: development and assessment of the framework. 
Finally, the thesis will conclude with an overall discussion of the work conducted and 
future directions.  
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Chapter 2: Framework Development 
 
2.1 Introduction 
 
In December 2016, the government in Ontario, Canada expanded the scope of pharmacists’ 
immunization administration authority to include 13 vaccine-preventable diseases in 
addition to the influenza vaccine.21 Although expansions in scope are generally well-
received, legislative changes alone do not directly result in practice changes. As observed 
with previous expansions to scope (for example, adapting and renewing prescriptions or 
conducting medication reviews), pharmacists’ uptake of new roles and responsibilities can 
be a gradual process, and there may be hesitation to implement it into practice.37-40  
A survey of community pharmacists, approximately two years following scope 
expansion in Ontario, found that the initial uptake of this scope expansion was slow, with 
94% of respondents reporting that they administered fewer than 10 of the new vaccinations 
added to their scope per month. Of note, these also included non-travel vaccinations, such 
as herpes zoster and human papillomavirus vaccinations, which represented the second- and 
fifth-most frequently administered vaccines, respectively.44 When asked about the new 
vaccinations, pharmacists cited varying levels of confidence with administering or 
recommending vaccinations for travel. This was attributed to lower familiarity with the 
vaccines and a perceived lack of clinical knowledge in travel medicine.44  
The results of the aforementioned survey align with previous studies regarding 
pharmacists that are beginners to the field of travel medicine. When reviewing the literature 
surrounding pharmacists’ care in travel medicine two themes emerge: 
1. Given extensive postgraduate training and experience in practice, pharmacists can 
positively impact health outcomes among travellers.27-31  
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2. Given the entry-level competencies required for pharmacists to practice, and lack 
of travel medicine training in pharmacy school curricula, most pharmacists without 
additional training or experience in travel medicine feel inadequately prepared to 
care for travelling patients. Further education and training regarding travel medicine 
for pharmacists are also often discussed as strategies to be explored by the studies 
with this theme.32-34 
Travel medicine expertise is often defined as an individual holding the International 
Society of Travel Medicine’s (ISTM) Certificate in Travel HealthTM (CTH®) and/or those 
who have completed a post-baccalaureate Doctor of Pharmacy (PharmD) with or without a 
hospital-based or primary care residency. These pharmacists exhibit confidence in their 
care, demonstrated through the creation of their own travel health clinics, perceived self-
competence, and strong patient outcomes. Pharmacists with travel medicine expertise have 
been found to consistently make evidence-based recommendations concordant with 
guidelines and their patients report a high level of satisfaction, including acceptance of 
recommendations and a sense of preparedness to manage health conditions that arise while 
travelling.27-31 However, the literature indicates deficiencies when evaluating care provided 
by pharmacists without additional travel medicine training. Although pharmacists are 
interested in travel medicine, they report not feeling adequately prepared for it, which has 
resulted in lack of patient education regarding oral typhoid vaccination, incomplete and/or 
incorrect travel advice, and recommendations regarding rabies pre- and post-exposure 
prophylaxis discordant with guidelines.32-34 
Related to pharmacists’ need for further training or education in travel medicine, the 
complexity of travel medicine (for example, regional differences in disease epidemiology, 
outbreaks, and changes in resistance patterns for infectious diseases) and need for 
individualized care is noted by pharmacists. Many preliminary studies have identified this 
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barrier and suggest that a gap in training in pharmacy school curricula is a contributor.4-6,36 
Pharmacy schools across the US and Canada do not have robust travel medicine 
competencies built into their core curricula, apart from immunization training, which tends 
to focus on influenza and other routine vaccinations.4-6,36 This lack of exposure during 
pharmacists’ training years as students likely impacts the provision of these services upon 
licensure. Further investigations into the scope of this problem need to be completed in 
order to make a definitive conclusion on the extent of this as a contributor and strategies to 
best address it. 
Given the historical pattern of uptake of expansions to pharmacy practice, similar 
challenges are anticipated regarding travel medicine activities, which may be amplified by 
additional practical factors such as lack of confidence with therapeutic knowledge in the 
area, lack of direction and support for the new service, and challenges with integrating the 
new service into the pharmacist’s existing workflow. Previous studies surveying 
pharmacists’ opinions have mentioned that an educational aid or practice tool may be a 
valuable facilitator to increase the uptake of travel medicine services.36,44  
To address these factors, we created and content-validated a questioning framework 
that pharmacists can use to triage risk factors among travelling patients. Pharmacists 
currently utilize various frameworks to guide patient assessments across a number of 
therapeutic areas. These frameworks are especially helpful to those new to the areas, such 
as students and new practitioners; however, even experienced clinicians continue to refer to 
frameworks to ensure a consistent approach to their patient assessments and documentation. 
For example, assessments related to patient self-care of common ailments often follow the 
“SCHOLAR” (Symptoms, Characteristics, History, Onset, Location, Aggravating factors, 
Remitting factors) and “MACS” (Medications, Allergies, Conditions, Social history) 
mnemonics.23 Similarly, the “OPQRST” (Onset, Palliation and Provocation, Quality and 
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Quantity, Region and Radiation, Signs and Symptoms, Temporal relationship) mnemonic is 
valuable to the assessment of pain.24 These frameworks provide health professionals with a 
structure to perform these assessments upon, adding to their confidence that their 
assessment will not miss any important elements that may affect their clinical decision-
making. 
The current literature contains no published frameworks to assist pharmacists in the 
area of travel medicine. While a number of clinical practice guidelines and publications, 
such as the Centers for Disease Control and Prevention’s (CDC) Yellow Book 2020: Health 
Information for International Travel, exist, little guidance is provided on how to interpret 
and implement this information into practice.2,3,26 This results in a wide variety of treatment 
experiences for the traveling patient and inconsistencies in the assessment of a traveling 
patient’s healthcare needs. Of the resources available, none are tailored for applicability to 
the pharmacy profession (e.g., different practice sites, scope of practice, approach to patient 
assessments).  
The objective of this study was to create an expert-informed validated clinical 
practice framework that pharmacists can use for risk assessment of traveling patients. The 
following article details the development and preliminary testing of the framework in 
community pharmacies and the impact this framework had on pharmacy practice in 
Ontario, Canada. 
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2.2 Methods 
 
Ethics approval for both the development and testing phases of the study was received from 
the University of Waterloo Research Ethics Committee (ORE #40021). Figure 6 describes 
the overall methodological process of this study. 
Figure 6 – Methodological process 
 
  
 
2.2.1. Framework Development 
 
The framework was developed in four stages: content generation, content judgement, 
validation, and final framework production. A panel of experts known to the authors was 
recruited to complete the first three stages. All interaction with the panel was done 
electronically through email communication.  
The criterion used to define our subject matter experts was a healthcare professional 
that had obtained the International Society of Travel Medicine’s Certificate in Travel 
HealthTM (CTH®). The CTH® is an internationally-recognized designation, which indicates 
that the person understands a wide body of knowledge related to travel medicine.10 
Currently there is no consensus on the number of subject matter experts recommended to 
develop or review an instrument.45 Although the more experts included decreases the 
probability of agreement due to chance and can better inform the framework’s 
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development, the maximum number is often up to 10 experts.45,46 In order to eliminate split 
decisions, while still gathering sufficient input, a panel of 9 experts was recruited.  
2.2.1.1. Content Generation 
An open-ended question was posted to the panellists to gather a list of items to consider for 
the framework: “What information do you gather to ascertain a traveling patient’s risk and 
what questions do you ask to obtain that information?” All items collected in this stage 
were collated, organized into broad domains, and considered in the following content 
judgement stage. 
2.2.1.2. Content Judgement 
Each item identified in stage 1 was included in a web survey, administered using 
QualtricsTM software (Qualtrics, Provo, UT, USA), which asked panellists to categorize 
each item as one of: essential; useful, but not essential; or not necessary. Only those items 
that were categorized as essential by more than half of the panellists (n ≥ 5) moved on to 
the content validation stage. Experts were also given the option at the end of the survey to 
provide any comments, such as the addition, deletion, or re-wording of any item(s), which 
would be considered in subsequent stages. 
2.2.1.3. Content Validation 
The quantitative index used to measure content validity for the framework was the Content 
Validity Index (CVI). The CVI involves the panel of experts rating each item based on 
content relevance or representativeness for an instrument and is considered the most widely 
utilized method of quantifying content validity.45 The panel was asked to rank the relevancy 
of each item that can be used in determining whether the traveller is a low- or high-risk 
patient. This was administered via another web survey using QualtricsTM software 
(Qualtrics, Provo, UT, USA). The ranking was based on a 4-point Likert scale (1: not 
relevant; 2: somewhat relevant; 3: quite relevant; 4: highly relevant). A 4-point scale was 
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selected over a 3- or 5-point rating scale because it does not contain a midpoint rating, 
forcing the expert to make a choice as opposed to being neutral or unsure, and also allows 
provides adequate information to calculate a CVI.45,47 
To quantify the framework’s validity, each item’s content validity index (I-CVI) 
was calculated, in addition to the overall Average Content Validity Index (Ave-CVI). The 
I-CVI was calculated “by counting the number of experts who rated the item as a 3 or 4 and 
dividing that number by the total number of experts, that is, the proportion of agreement 
about the content validity of an item.”48 There are many ways to calculate an instrument’s 
Ave-CVI (e.g., the proportion of items rated relevant across experts can be averaged, the I-
CVIs can be summed and divided by the number of items, or the total of number of ratings 
as a 3 or 4 can be counted and divided by the total number of ratings); for this study, all I-
CVIs were averaged to calculate the Ave-CVI. It is important to note that all three methods 
for calculating the Ave-CVI will yield the same value, but it has been suggested that 
averaging the I-CVIs is “more related to the quality of the items rather than the 
performance of experts.”49 As a valid framework is defined as having an Ave-CVI ≥ 0.90, 
if not achieved in the first round of surveys, items will be revised and recirculated to the 
panel until this value is obtained. 
2.2.1.4. Construction of The Framework 
Construction of the framework involved the organization of each included item into 
domains using a checklist format to facilitate ease of use in practice. Following content 
validation, a preliminary framework was made. To ensure understandability and face 
validity, 3 Canadian-licensed pharmacists that had been practicing for less than 5 years and 
had no formal training or self-identified expertise in travel medicine were asked to review 
the framework for clarity and provide feedback, as they represent a potential user group of 
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the framework. The framework was subsequently revised until each of the pharmacists 
expressed satisfaction with it. 
2.2.2 Framework Testing 
 
2.2.1. Study Design and Recruitment 
To obtain an initial evaluation of the framework, we used a pre-and post-test study design 
with the availability of the framework being the intervention. Pharmacist participants were 
recruited using personal contacts of the researchers, including previous participation in 
travel medicine studies. Recruitment of the participants was ongoing from January to April 
2019. The inclusion criteria for the pharmacists was:  
1. Current practice is in a community pharmacy.  
2. Part A (able to provide direct patient care) licensure through the Ontario College 
of Pharmacists (OCP) or 4th year entry-to-practice PharmD student currently on 
clinical practice rotation. 
3. Does not currently hold CTH® designation from ISTM. This exclusion was 
applied as it is a global indicator that the individual has an advanced level of travel 
medicine knowledge,10 whereas this framework was developed specifically for 
pharmacists without experience or expertise in travel medicine. 
2.2.2.2. Data Collection 
The testing took place from March to August 2019 at community pharmacies across 
Ontario, Canada. During this study period, pharmacists were instructed to “Please utilize 
the framework in your practice, as you deem fit, to triage patients as either high or low risk 
travellers.” If the framework was used, the pharmacists were asked to record metrics on the 
back of the framework. These metrics included the date used, estimated triage time 
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(minutes), whether the patient was referred or not and the reasoning behind the decision 
made. These metrics were then faxed to the researchers at the end of each month.  
At the time of enrolment, participants were asked to complete a survey to gather 
baseline information on their demographics, practice-related characteristics, and current 
practices regarding travel medicine (Appendix B). Pharmacists were also asked to complete 
an online survey in September 2019 once the study period had concluded. This survey 
gathered feedback on the framework’s feasibility and impact on pharmacy practice 
(Appendix C). Feedback was gathered using open-ended questions that allowed participants 
to describe the main advantages and disadvantages of the framework, as well as provide 
any suggestions for improvement and detail how pharmacists saw the framework being 
incorporated into their pharmacy workflow. 
All surveys were administered using QualtricsTM software (Qualtrics, Provo, UT) 
with questions collecting both quantitative and qualitative data, using free-text answer 
formats. Descriptive statistics were performed using Microsoft Excel for Windows 10, 
Version 1902 (Redmond, WA). 
 
 
 
 
 
 
 
  
33 
 
2.3 Results 
 
2.3.1. Framework Development 
As pharmacists are the intended primary audience for the tool, seven of the nine experts 
recruited were pharmacists, and the remaining two were family physicians (Table 2). 
Table 2 – Demographics of expert panellists 
Panellist Profession Gender Year of 
Licensure 
Year 
CTH® 
Achieved 
Practice 
Setting 
Canadian 
Province 
of Practice 
1 Physician Female 1999 2007 Medical 
Clinic 
Ontario 
2 Physician Male 2011 2013 Medical 
Clinic 
Ontario 
3 Pharmacist Female 2009 2017 Community 
Pharmacy 
British 
Columbia 
4 Pharmacist Female 1999 2011 Community 
Pharmacy 
Nova 
Scotia 
5 Pharmacist Female 1994 2015 Community 
Pharmacy 
Alberta 
6 Pharmacist Male 1993 2015 Consultant Ontario 
7 Pharmacist Male 2012 2014 Community 
pharmacy 
British 
Columbia 
8 Pharmacist Female 1999 2011 Travel 
Clinic 
Alberta 
9 Pharmacist Female 2013 2015 Community 
Pharmacy 
Ontario 
Panellists submitted their responses online for content generation (stage 1) in a variety 
of formats, including detailing their thought process with a traveller, or submitting resources 
and/or questionnaires used in their practices. A total of 114 unique items were identified in 
stage 1, which were organized into 6 domains of information gathering, as indicated in Table 
3. 
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Table 3 – Domain identification and definition 
Domain Definition 
Who? Patient specific-factors (e.g., medical conditions) 
What? Itinerary-specific factors (e.g., activities planned during travel) 
When? Timeframe of travel (departure date, duration at destination) 
Where? Country(ies) and region(s) visited, including order if more than one 
Why? Motivation for travel (e.g., visiting friends and relatives) 
How? Travel style and history (e.g., previous travel experience) 
Rankings on the essentialness of the 114 items in stage 2 are provided in Appendix 
D. The response rates of panellists for stages 1 and 3 of the study were each 100%. However, 
the response rate for stage 2 was 78% (n = 7) due to the unavailability of two panellists during 
the data collection period. Despite fewer panellists participating in stage 2, the decision was 
made to still require 5 or more of them to deem an item to be essential for it to be included 
in the content validation stage. 
In total, 64 items were categorized as essential and moved on to content validation. 
At this point, the “How” domain was removed completely from the final framework as none 
of its items were ranked essential, leaving the 5 ‘W’ domains of who, what, where, when, and 
why. A full breakdown of how those 64 items were ranked according to relevancy, including 
their I-CVI, can be found in Table 4. The Ave-CVI across all items was calculated to be 0.91. 
Upon re-consideration, 2 items regarding dining were switched from the “Where?” to the 
“What?” domain for appropriateness. Additionally, further information on the definition of 
immunocompromised status and a list of countries that could be considered high-risk was 
added following framework review by practicing pharmacists. 
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Table 4 – Framework item and average content validation summary 
Item Not 
Relevant 
(%, n) 
Somewhat 
Relevant 
(%, n) 
Quite 
Relevant 
(%, n) 
Highly 
Relevant 
(%, n) 
I-CVI 
Who? 
Diabetes 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Blood or clotting disorder 11.1% (1) 0% (0) 22.2% (2) 66.7% (6) 0.89 
Heart disease or arrhythmia 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Seizure disorder 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Emotional/psychiatric condition(s) 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Inflammatory bowel disease 0% (0) 33.3% (3) 22.2% (2) 44.4% (4) 0.67 
Thymus disorders (e.g., myasthenia 
gravis) 
0% (0) 11.1% (1) 11.1% (1) 77.8% (7) 0.89 
Liver or kidney disease 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Damaged or removed spleen 0% (0) 11.1% (1) 22.2% (2) 66.7% (6) 0.89 
Organ or bone marrow transplant 11.1% (1) 0% (0) 0% (0) 88.9% (8) 0.89 
Recent chemotherapy or radiation (<4 
months) 
11.1% (1) 0% (0) 0% (0) 88.9% (8) 0.89 
HIV, AIDS, immune suppressed or 
immunocompromised 
11.1% (1) 0% (0) 0% (0) 88.9% (8) 0.89 
Currently pregnant 0% (0) 0% (0) 0% (0) 100% (9) 1 
Planning to get pregnant soon after 
travel 
0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Breastfeeding 0% (0) 11.1% (1) 55.6% (5) 33.3% (3) 0.89 
Blood thinners (e.g., warfarin, 
clopidogrel) 
0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Corticosteroids 0% (0) 0% (0) 11.1% (1) 88.9% (8) 1 
Chemotherapy or other anti-cancer 
medications 
0% (0) 0% (0) 0% (0) 100% (9) 1 
Quinine, quinidine, or other cardiac 
drugs 
0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Medications for mood disorder or 
emotional problems 
0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Medications to control seizures 0% (0) 0% (0) 66.7% (6) 33.3% (3) 1 
Age 0% (0) 0% (0) 55.6% (5) 44.4% (4) 1 
Date of birth (for immunization 
purposes) 
0% (0) 22.2% (2) 55.6% (5) 22.2% (2) 0.78 
Allergy to streptomycin, gentamicin 
or neomycin etc. 
0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Traveling with children 0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Awareness of immunization status 0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Serious reaction in the past with 
vaccines 
0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Where?      
Country/Countries 0% (0) 0% (0) 11.1% (1) 88.9% (8) 1 
Cities/Regions 0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Dates for travel for each country 
and/or city (if more than one) 
0% (0) 0% (0) 77.8% (7) 22.2% (2) 1 
Rural/urban areas 0% (0) 0% (0) 66.7% (6) 33.3% (3) 1 
Hostels 0% (0) 11.1% (1) 55.6% (5) 33.3% (3) 0.89 
Friend/family’s home 0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Camping 0% (0) 0% (0) 55.6% (5) 44.4% (4) 1 
When? 
Departure/arrival dates 0% (0) 55.6% (5) 22.2% (2) 22.2% (2) 0.44 
Last minute traveler (<4 weeks) 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
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Length of stay 0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Why? 
Visiting friends/family 0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Athletic competition 0% (0) 44.44% (4) 33.33% (3) 11.11% (1) 0.44 
Religion (e.g., Hajj) 0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Medical tourism 0% (0) 0% (0) 11.1% (1) 88.9% (8) 1 
Sexual tourism 0% (0) 0% (0) 11.1% (1) 88.9% (8) 1 
Humanitarian work 0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Adventure 0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Research/education 0% (0) 33.3% (3) 66.7% (6) 0% (0) 0.67 
Adoption 0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
What? 
Scuba diving 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Going to high altitude 0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Safari 0% (0) 33.3% (3) 55.6% (5) 11.1% (1) 0.67 
Spending time in rural communities 
or remote areas 
0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Adventure travel 0% (0) 11.1% (1) 55.6% (5) 33.3% (3) 0.89 
Close contact with animals 0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Providing medical care 0% (0) 0% (0) 11.1% (1) 88.9% (8) 1 
Exposure to extreme heat or cold 0% (0) 0% (0) 44.4% (4) 55.6% (5) 1 
Jungle 0% (0) 11.1% (1) 44.4% (4) 44.4% (4) 0.89 
Cave exploration 0% (0) 0% (0) 66.7% (6) 33.3% (3) 1 
Hiking or trekking 0% (0) 11.1% (1) 66.7% (6) 22.2% (2) 0.89 
Rafting or kayaking 0% (0) 22.2% (2) 55.6% (5) 22.2% (2) 0.78 
Restricted work camp 0% (0) 22.2% (2) 55.6% (5) 22.2% (2) 0.78 
Motorcycle 0% (0) 11.1% (1) 33.3% (3) 55.6% (5) 0.89 
Backpacking 0% (0) 22.2% (2) 33.3% (3) 44.4% (4) 0.78 
Trekking 0% (0) 33.3% (3) 33.3% (3) 33.3% (3) 0.67 
Friend/family cooking 0% (0) 0% (0) 22.2% (2) 77.8% (7) 1 
Street food and vendors 0% (0) 0% (0) 33.3% (3) 66.7% (6) 1 
Ave-CVI = 0.91 
 
The final version of the framework (Figure 7) is a concise one-page tool to identify 
risk factors in traveling patients. While pharmacists with any level of travel medicine 
experience are welcome to use the framework, it is primarily meant for those with minimal 
experience. As the intended user group consists of community pharmacists new to the field 
of travel medicine, the items are primarily posed in Yes/No question format, where a 
positive response to any item may indicate a need for referral to an experienced travel 
medicine healthcare professional. Those items that are posed as open-ended questions allow 
for the pharmacist to use their judgement on determining whether the patient’s response is a 
criterion for referral. If these answers are deemed low-risk and the patient has answered 
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“no” to all the other questions, the patient can be classified as a low-risk traveller that could 
likely have a travel consultation done by that pharmacist. 
Figure 7 – Final version of The 5W Approach to Travel Risk Identification framework 
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2.3.2. Framework Testing 
Of the 19 respondents that reviewed the invitation letter and expressed interest in testing the 
framework, nine were excluded for failing to provide consent to participate and two 
participants were excluded due to failure to complete the pre-study survey. One participant 
failed to complete the post-study survey. The demographics of the eight respondents 
completing the study is provided in Table 5. Half of the respondents indicated practicing in 
a chain pharmacy and in the capacity of a staff pharmacist. Most (n=5) practiced in South 
West Ontario, consistent with the greater population density in this region of the province.50 
Most pharmacists (n=5) had 11 or more years of experience, all were authorized to 
administer injections, and most had a Bachelor’s degree as their highest level of pharmacy 
education. Additional training was completed by one participant through the American 
Pharmacists Association’s Pharmacy-Based Travel Health Services continuing education 
program.51 
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Table 5 – Pharmacist participant characteristics 
Characteristic 
Frequency 
(%) 
(n=8) 
Type of community pharmacy  
Chain 4 (50.0%) 
Independent 1 (12.5%) 
Banner 3 (37.5%) 
Role in pharmacy  
Staff pharmacist 4 (50.0%) 
Owner 2 (25.0%) 
Pharmacy student 2 (25.0%) 
Designated manager1 3 (37.5%) 
Location in Ontario  
Central South 1 (12.5%) 
Central West 1 (12.5%) 
East 1 (12.5%) 
South West 5 (62.5%) 
Years in a community pharmacy practice (licensed pharmacists only, n=6) 
Less than 1 1 (16.7%) 
11-20 4 (66.6%) 
21-30 1 (16.7%) 
Average number of hours worked per week (licensed pharmacists 
only, n=6)  
8-16 2 (33.3%) 
25-32 1 (16.7%) 
33-40 2 (33.3%) 
More than 40 1 (16.7%) 
Gender  
Male 3 (37.5%) 
Female 5 (62.5%) 
Authorized to administer injections  
Yes 8 (100.0%) 
Education (licensed pharmacists only, n=6), select all that apply  
BSc Pharmacy 5 (83.3%) 
Entry-to-practice PharmD 1 (16.7%) 
1 Participants had the option to select designated manager of the pharmacy in addition to other roles. 
 
All pharmacists that reported some experience with the additional vaccines added to 
the scope of practice to varying degrees. However, their approach when interacting with a 
travelling patient varied. Prior to this study, when a patient presented to the pharmacy 
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inquiring on precautions they need for an upcoming destination, participants reported they 
may provide information on general precautions (n=7), perform a complete consultation for 
less complex patients (e.g., all-inclusive resort in the Caribbean, cruise) and refer all others 
(n=6), refer all patients to a travel clinic or to their physician (n=3), refer patients to online 
or paper resources with more information (n=3), or other (n=1) which was described as 
“review complex patients for risks associated [with pre-existing medical conditions] and 
notify GP (e.g., anticoagulation).” 
2.3.2.1. Attitudes and Beliefs Towards Travel Medicine 
All pharmacists expressed a high degree of willingness to incorporate travel medicine into 
their practices. The primary motivators included travel medicine questions being 
increasingly frequent from their patient populations and pharmacists’ self-interest in travel 
medicine. As Pharmacist 3 explained, “travel is more and more common and with 
pharmacists able to give some vaccinations it should be an expectation of patients to get 
help in any retail pharmacy.” Pharmacist 6 commented that “[travel medicine] is a relevant 
and essential part of patient care that most times does not require a lot of effort.” The 
primary barriers cited preventing the participants from starting travel medicine services 
includes lack of knowledge regarding travel medicine, lack of time, and lack of prescribing 
authority. Regarding knowledge, Pharmacist 5 stated “pharmacists underestimate the 
complexity of knowledge required for travel medicine practice. Pharmacists do not have 
enough knowledge nor training on vaccinology or disease knowledge required for a travel 
consult. If a consult is not done properly, we are doing patients a disservice.” When 
referring to the inability to prescribe, Pharmacist 2 noted that “some physicians will accept 
recommendations from the pharmacist and send an Rx, but others refer everyone to a travel 
clinic.” It is also important to note that participants appeared to use the terms “counselling” 
and “travel consultation” interchangeably through the survey questionnaires. Its 
implications are detailed in the discussion section. 
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2.3.2.2. Framework Feasibility 
The framework was only utilized in March and April of the 6th month study period, 
totalling three interactions. The results of the pharmacists’ interactions are recorded in 
Table 6. 
Table 6 – Framework metrics collected by pharmacists 
Date used 
(YYYY/MM/DD) 
Estimated 
triage time 
(mins) 
Did you 
refer the 
patient? 
What was the reason 
for referring/not 
referring 
If you did not 
refer, what was 
the course of 
action? 
2019/03/26 45* Yes 
“Needed yellow fever 
vaccine, proof of polio 
vaccination and 
malaria 
chemoprophylaxis” 
 
 
2019/03/28 35* Yes 
“Needed yellow fever 
vaccine and proof of 
polio vaccination” 
 
 
2019/04/20 15 No 
“Did not refer as not 
high risk” 
“Patient had 
TwinRix® 
[combined 
hepatitis A and 
B vaccine] 
previously and 
decided to get 
Dukoral® [oral 
cholera 
vaccine]” 
* Interaction was performed by 4th year entry-to-practice PharmD student. 
 
Despite the framework not being used by all pharmacists during the study period, 
feedback was sought from all participants in the post-test survey (n=7). Overall, it was 
viewed as a helpful tool that can guide pharmacists with questions and identify complex 
patients that may need referral beyond a pharmacist’s scope. Benefits included being simple 
to use and asking the important questions for assessing a travelling patient while providing 
a structure for pharmacists to follow. As Pharmacist 6 commented, “[you] can follow an 
algorithm to assist in guiding decisions, especially if encountering a complex situation.” 
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Participants did note that the framework contained a lot of text, which resulted in a time 
investment required to orient oneself to the intended flow. Time investment in completing 
the framework could also be a limitation if it is identified near the end of the framework 
that the patient has a complicating factor warranting referral. As Pharmacist 4 explained, 
“[the] patient might be upset that after all the questions and discussion, they still have to go 
to the travel clinic.” While it was generally noted as a great tool for most pharmacists, it 
may be less useful for pharmacists with more education in travel health, who may have 
their own preferred format.
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2.4 Discussion 
 
2.4.1. Framework Development 
Following expert-informed content generation, judgement, and validation, we produced a 
succinct clinical practice framework intended for community pharmacists to triage the risk 
profiles of traveling patients. It is the first tool of its kind targeted to pharmacists to identify 
patients who may be safely assessed in a community pharmacy by a pharmacist with 
limited travel medicine training or experience, versus those who would benefit from referral 
to another clinician. The 64 items included largely align with pre-travel risk assessment 
recommendations included in the CDC’s Yellow Book and other references2,3,26,52 and are 
grouped into five broader domains (the 5 Ws of Who, What, Where, When, and Why) for 
ease of understanding and use. 
Successful content validation, defined as Ave-CVI ≥ 0.90,48 was achieved after only 
one round of content validation. Additionally, it should be noted that the expert panellists 
practiced in different locations across Canada, reflecting perspectives from different 
provinces where scope of practice can vary. Depending on the province, pharmacists’ scope 
of practice can range from independently prescribing for all conditions related to travel 
medicine, through prescribing within certain legislative conditions or with a medical 
directive, to only being able to immunize against travel-related vaccine preventable 
diseases without prescribing authority.12 The inclusion of a broad sample of pharmacists 
practicing under different scopes in the expert panel is expected to enhance the 
framework’s applicability across jurisdictions. 
However, our work is not without limitations. The expert panel’s degree of input 
was limited, as all feedback was performed via online surveys consisting largely of 
multiple-choice questions. Open-ended feedback or rationale for selections was not sought, 
and panellists did not have the opportunity to discuss their selections with the other 
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panellists. For example, while acceptable I-CVI values are those above or equal to 0.78,48 6 
of the 64 items included in stage 3 did not meet this standard. Further revision of these 
items with the aim of improving their I-CVI was not performed. Additionally, the 
interpretation of each item’s relevancy was left solely to the discretion of the individual 
panellists. No further instruction was given or sought regarding the difference between 3 - 
Quite Relevant and 4 - Highly Relevant; however, this likely didn’t significantly affect the 
calculation of either the I-CVI or Ave-CVI as these depend on selecting either 3 - Quite 
Relevant or 4 - Highly Relevant. Another limitation was that two expert panellists were 
unavailable to provide input in the content judgement survey (stage 2), while all nine 
experts were able to participate in content generation (stage 1) and validation (stage 3). 
While the number of participants at each stage was sufficient,45,46,48 this discrepancy should 
be noted, as it represents slight differences in panel composition across each stage. 
Pharmacists’ increasing involvement with clinical activities, particularly with travel 
medicine, is an emerging international trend, reflected by the creation of a Pharmacists 
Professional Interest Group within the International Society of Travel Medicine.11 Previous 
travel medicine guidance documents on information gathering and risk assessment have 
either been targeted to the medical community or had limited accessibility to the broad 
pharmacist population (for example, embedded within continuing education modules, or 
internal questionnaires/frameworks created by pharmacy corporations). To our knowledge, 
this is the first framework for pharmacists to be published and, importantly, to also have its 
content validated. As a result, we are unable to compare our results to previous work. 
2.4.2. Framework Testing 
Overall, feedback on the framework from the pharmacist and final-year student participants 
was positive, with it reported to be an advantageous tool that is simple to use and can 
provide structure to guide pharmacists through travel-related interactions. However, it may 
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not provide as much benefit for a pharmacist with above average travel medicine 
knowledge, which is to be expected as the intended audience was pharmacists new to travel 
medicine assessments. 
The most significant limitation encountered in this feasibility study was the data 
collection period, as it ran from March to August 2019, which falls outside of the peak 
travel season for many Canadians who often opt to travel in the colder months of the year 
(November–April).53 Indeed, all uses of the framework occurred before May. In the 
monthly communications with the researchers, pharmacists reported throughout the study 
period that patients had not been coming in for travel advice, which hindered their ability to 
use the framework. The timing of the study is a potential reason for the low recruitment of 
pharmacists. The small sample size and minimal usage of the framework also affected the 
validity of the survey pharmacists were asked to complete once the data collection period 
concluded in August. Particularly, commentary provided on the framework from those who 
have not actually used it is not substantiated by experience with its use in practice. Finally, 
it should be noted that two of the three uses of the framework in practice was by pharmacy 
students. Despite not yet being licensed to practice independently, student participants were 
in their final year clinical practice rotations and can therefore be assumed to have similar 
knowledge and skills as a newly-licensed practitioner. One may argue that their level of 
exposure to formal travel medicine training may actually exceed that of many practicing 
pharmacists, as vaccines for travel is required learning in the second year of their program 
at the University of Waterloo, as is a two-hour lecture on travel medicine in their third year. 
However, their status as a student and need to potentially discuss assessments with their 
pharmacist preceptor may have contributed to the longer framework completion times 
observed among the trials conducted by the student participants. 
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Several studies have concluded that an educational aid or practice tool for 
pharmacists may serve as a facilitator to increase uptake of travel medicine services;36,44 
however, to date, no published studies have trialled the use of such a tool. As the first study 
to explore this type of work, a few implications on practice can be made. The low or non-
existent use of the framework between May and August of the study period, due to patients 
not presenting to the pharmacist with travel-related inquiries, can impact the rate at which 
pharmacists are able to apply this expanded scope of practice in Ontario. As seen with our 
previous study on the uptake of immunization services, pharmacists’ confidence was 
directly related to the duration of scope availability and their frequency of exposure to it.44 
If there are limited opportunities for pharmacists to provide travel medicine services for 
half of the year due to low demand in the off-season for travel, it can be expected that an 
even slower rate of uptake may be observed relative to other clinical services provided 
year-round. For example, pharmacist prescribing for minor ailments has the potential for 
pharmacists to partake in that scope on a regular basis. That same regularity of exposure 
cannot necessarily be said for travel medicine.  
Another finding to investigate in future research is the quality of the care that 
pharmacists are providing for travelling patients. Despite participants self-identifying 
themselves as beginners in travel medicine, 75% (n=6) of the pharmacists reported that 
their pharmacy offered pretravel consultations to their patients. Interestingly, only one 
participant reported charging a fee for this consultation. It would be highly unusual for 
pharmacies to not charge a fee for a comprehensive consultation that may take 30–60 
minutes to complete.52 This frequency is lower than that reported by respondents to our 
previous survey of Ontario pharmacists, which found that 35% of pharmacies offering 
travel consultations charged patients for this service.44 As previously mentioned, the 
pharmacist participants appeared to use the terms “counselling” and “consultation” 
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interchangeably, which may provide an explanation for these discrepant findings. The 
implications of this are two-fold:  
1. Just because a pharmacy offers pretravel consultation services does not 
necessarily indicate that the pharmacists are actively performing them. 
2. Pharmacists may have differing definitions of what they consider to be a pretravel 
consultation.  
Variability in how pharmacists conduct pretravel consultations (e.g., via 
appointment or as an add-on to routine counselling on prescription or non-prescription 
drugs) can be a factor in this discrepancy as well. Variability in approach and 
comprehensiveness is not unique to travel medicine, as it was also observed following the 
introduction of the MedsCheck medication review program in Ontario.54 For example, 
although approximately half of Ontarians with diabetes received an annual MedsCheck for 
Diabetes review, only 2.7–4.1% received a follow-up assessment, despite the use of 
potentially complex medications regimens for diabetes and comorbid conditions that 
warrant ongoing monitoring.54 Although clinical effectiveness and high patient satisfaction 
have been observed from pretravel consultations performed by pharmacists with expertise 
in travel medicine,27-31 it remains to be determined if similar quality and consistency is 
observed when these services are offered by non-expert pharmacists. As one participant 
commented, “it would be a dis-service to the community if pharmacists are giving 
inadequate or bad advice. Pharmacy as a profession should not promote a service when 
members are not knowledgeable. Just because pharmacists are able to administer vaccines 
does not mean that pharmacists understand the disease the vaccine is there to protect.” 
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2.5 Conclusion 
 
It has been established that the unique knowledge base required to practice in travel 
medicine contributes to lack of confidence among pharmacists in providing care for 
travellers. The 5W Approach to Travel Risk Identification provides a clinical practice 
framework for pharmacists that aims to address the challenges new practitioners in travel 
medicine may face when performing information gathering and general risk assessment of 
travellers. By being expert-informed and content-validated, this framework is expected to 
support pharmacists in the safe and effective identification of low-risk patients who may be 
manageable by a generalist practitioner versus those who may benefit from referral to 
another clinician with travel medicine expertise. Despite a small sample size of trials, the 
framework will be revisited as a potentially helpful tool that can guide pharmacists in the 
assessment of travelling patients. Further work needs to be performed to understand the full 
extent of the framework’s feasibility and impact on practice, as well as pharmacists’ 
understanding of what constitutes a pretravel consultation. Feasibility testing will be 
expanded to pharmacists across Canada, including different provincial scopes of practice, 
during peak travel season in the 2019–2020 period. 
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Chapter 3: Overall Discussion, Conclusion and Future 
Directions 
 
3.1 Overall Discussion 
 
3.1.1 Contribution to the Fields of Travel Medicine and Pharmacy Practice 
The work of this thesis sought to address the potential barriers of travel medicine in 
pharmacy practice and fill a need that pharmacists have expressed would be a facilitator in 
the uptake of travel medicine. The product of this thesis was a framework that 
accomplished the following: 
1. Amalgamated various risk factors in an approach that is applicable to traveller risk 
assessment in the pharmacy practice setting. A significant number of pharmacists 
likely have not had comprehensive training or education of travel medicine in their 
pharmacy education. This tool bridges the knowledge gap of patient evaluation for 
travel medicine by accustoming the pharmacist to the types of questions and patient 
factors that affect a traveller’s level of risk. 
2. Guides a pharmacist through a systematic process of identifying travel risk in a 
patient. The questions are formatted in a yes/no fashion to easily identify the main 
risks of travel. However, there are still questions that pharmacists are able to use 
their professional judgment on (e.g. destination country) to determine the level of 
risk and the best healthcare professional suited for that patient’s travel needs.  
3. Is the first practice tool, to our knowledge, that brings travel medicine and 
pharmacy practice together that’s content has been validated (Ave-CVI =0.91). 
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3.1.2 Limitations 
The significant limitation of this thesis lies in Chapter 3, the testing of the framework in 
pharmacy practice. Two specific areas are the weaknesses in the testing phase: 
1. Number of pharmacists recruited 
2. Testing period 
As previously mentioned, while a number of pharmacists expressed interest in the 
study, only a small number of pharmacists actually completed the pre-test and post-test 
surveys. The recruitment strategies employed included using previous research participants 
that have expressed interest and consent in being contacted for future studies, networking 
with professional pharmacist contacts, and promoting the study through the University of 
Waterloo School of Pharmacy’s Regional Clinical Coordinators to recruit 4th year PharmD 
students on rotations. 
Ethics approval for the community pharmacy testing phase was received on 
February 15, 2019. Therefore, the study period of the framework in pharmacy practice took 
place from March to August 2019. Unfortunately, this missed the peak travel season for 
many Canadians, and as a result the peak timing of when pharmacists received travel-
related questions from patients. Pharmacist participants reported the lack of patients 
presenting to the pharmacy with travel-related concerns as affecting the use of the 
framework and obtaining data regarding its use. 
While this study was a feasability test, its limitations are noted. Specific actions to 
address the limitations of this study will be further addressed in 3.3 Future Directions. 
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3.2 Conclusion 
 
Travel medicine is a unique field of patient care for any healthcare practitioner. As the 
scope of practice expands for the pharmacy profession, pharmacists can be expected to 
participate in this area of care despite additional formal education or training. Travel 
medicine has a large focus on preventative care, with a cornerstone of the decision-making 
being able to identify risk in a travelling patient and provide appropriate care to mitigate 
that risk. The 5W Approach for Travel Risk Identification has been created to aid in this 
process. Suitable for pharmacists, the factors considered in the tool are relevant to the field 
of travel medicine as exhibited in its Ave-CVI of 0.91. What is unknown at this point is the 
impact the framework may or may not have on pharmacy practice and patient outcomes. 
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3.3 Future Directions 
 
In order to assess the full potential impact and feasibility of the 5W Approach for Travel 
Risk Identification, a second study will be performed by the MSc candidate outside of the 
requirements of this thesis. This study will take place from November 2019 to April 2020, 
inclusive, in order to capture the peak travel season for Canadians and, subsequently, travel 
medicine inquiries for pharmacists. One difference in this testing is that it will be open to 
any pharmacist in Canada, excluding territories, that does not have their CTH®. The 
challenges of travel medicine are not just limited to Ontario pharmacists, it can be a 
difficult adjustment to any pharmacist in Canada. However, one varying factor is the types 
of barriers each province has in the provision of travel medicine service (e.g., ability to 
prescribe). This will be accounted for in the pre-test survey and analysis of results. The 
recruitment will also differ. As opposed to the researchers contacting and identifying 
individuals that may be interested in participating, the researchers will place advertisements 
in newsletters of each provincial regulatory college and advocacy organization. The 
advertisement will link to the pre-test survey to input pharmacists’ contact information that 
will later be de-identified. After the successful completion of the survey, the framework 
will be emailed to the participants for them to use in practice. The post-test survey and 
monthly check-ins will remain the same. Pharmacists will email completed metrics monthly 
to the researchers. Additionally, any pharmacist who completes the pre-and post-test 
surveys and has used the framework at least 10 times during the study period (average 2 per 
month) will be enrolled in a draw. All enrolled pharmacists will be entered to win an iPad, 
the winner will be selected randomly. As for the analysis, the main parts of the survey that 
will undergo statistical analysis are the sections where pharmacists will self-rank their 
confidence and knowledge levels related to different parts of the ISTM’s Body of 
Knowledge and OCP’s Pharmacist Practice Assessment Criteria for a control.55,56 Although 
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the Pharmacist Practice Assessment Criteria is from the Ontario College of Pharmacists, it 
is based off the National Association of Pharmacy Regulatory Authorities Model Standards 
of Practice for Canadian Pharmacists and, therefore, has applicability for pharmacists 
across Canada.57 The scale is from 0 (non-existent/minimal) to 100 (full). Due to the scale 
and pre/post nature of the experiment, the Wilcoxon paired test will be used to examine 
change. In addition to the dissemination of these findings via publication, a potential next 
step in knowledge translation is the provision of sample cases to illustrate the framework’s 
intended use. This can be tied to continuing education related to pretravel consultations, 
which is also sought by pharmacists as a facilitator for travel medicine.36,44 
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Appendix 
 
Appendix A - CTH® Examination Breakdown 
 
1. Epidemiology (10%) 
Basic Concepts (e.g., morbidity, mortality, incidence, and prevalence) 
Geographic specificity/global distribution of diseases and potential health hazards 
2. Immunology/Vaccinology (20%) 
Basic concepts and principles (e.g., live vs. inactivated vaccine, measurement of immune 
response) 
Handling, storage, and disposal of vaccines and related supplies 
Types of Vaccines/Immunizations/Immunobiologics. Indications/contraindications, routes 
of administration, dosing regimens, duration of protection, immunogenicity, efficacy, 
potential adverse reactions and medical management of adverse reactions associated with 
the following vaccinations/combination vaccinations: 
• Bacille Calmette-Guerin 
• Cholera 
• Diphtheria 
• Encephalitis, Japanese 
• Encephalitis, tick-borne 
• Haemophilus influenzae type B 
• Hepatitis A 
• Hepatitis B 
• Hepatitis A and B combined 
• Human Papilloma Virus 
• Immune globulin 
• Influenza 
• Measles 
• Meningococcal 
• Mumps 
• Pertussis 
• Pneumococcal 
• Poliomyelitis 
• Rabies 
• Rotavirus 
• Rubella 
• Tetanus 
• Typhoid 
• Varicella 
• Yellow Fever 
• Zoster 
• Other combined vaccines 
• Other 
3. Pretravel Assessment/Consultation (35%) 
Patient Evaluation 
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• Assessment of fitness/contraindications to travel (e.g., pre-existing illness, fitness to 
fly) 
• Evaluation of travel itineraries/risk assessment (e.g., pre-existing activities, travel to 
rural vs. urban areas) 
• Relevant medical history (e.g., previous vaccinations, allergies, chronic illness, 
mental health history and concurrent medications) 
• Screening for good mental health and personal resilience to stress in hostile 
environments  
Special Populations. Unique management issues pertaining to the following populations: 
• Athletes 
• Business travellers 
• Elderly travellers 
• Expatriates/long term travellers 
• Immigrants 
• Infants and children 
• Travel for the purpose of international adoption 
• Missionaries/volunteers/health clinicians/humanitarian health workers  
• Pregnant travellers and nursing mothers 
• Teachers, trainers, and students 
• Travellers with chronic diseases (e.g., diabetes, chronic obstructive pulmonary 
disorder, cardiovascular diseases, mental health illnesses) 
• Travellers with disabilities 
• Travellers to hostile environments (e.g., journalists, armed service personnel, 
scientists, academics) 
• Travellers who are immunocompromised, including AIDS and HIV 
• VFR's (those visiting friends and relatives in their countries of origin) 
• Other 
Special Itineraries. Unique management issues associated with the following 
activities/itineraries: 
• Armed conflict zones 
• Cruise ship travel/sailing 
• Diving 
• Extended stay travel 
• Extreme/wilderness/remote regions travel 
• High altitude travel 
• Last minute travel 
• Mass gatherings (e.g., the Hajj) 
• Travel for the purpose of receiving medical care 
• Natural disaster areas 
• Sex tourism 
• Travel to areas experiencing disease outbreaks 
• Other 
Prevention and Self-Treatment: 
Chemoprophylaxis: 
• Altitude Illness 
• Leptospirosis 
• Malaria 
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• Travellers’ diarrhea 
• Other 
Personal protective measures (e.g., restriction of outdoor activity at dawn and dusk) 
and barrier protection (e.g., bed nets, insect repellents) 
Self-treatment: 
• Diarrhea 
• Malaria 
• Other 
Travel health kits 
Other travel medicine medications and pharmacological issues 
Risk communications regarding: 
• Animal contact (including birds) 
• Close interpersonal contact (e.g., sexually transmitted diseases) 
• Contact with fresh and salt water 
• Food consumption  
• Safety and security 
• Walking barefoot 
• Water consumption and purification 
• Antimicrobial resistance 
• Other (e.g., skin trauma, infection) 
4. Diseases Contracted During Travel (12%). Geographic risk, prevention, transmission, 
possible symptoms and appropriate referral/triage of: 
Diseases Associated with Vectors: 
• African Tick Bite Fever 
• Chikungunya 
• Dengue 
• Encephalitis, Japanese 
• Encephalitis, tick-borne 
• Filariasis (e.g. Loa loa, bancroftian, onchocerciasis) 
• Hemorrhagic fevers 
• Leishmaniasis 
• Lyme, anaplasma, babesia 
• Malaria 
• Plague 
• Rickettsia (typhus) 
• Rift Valley Fever 
• Trypanosomiasis, African 
• Trypanosomiasis, American (Chagas disease) 
• West Nile 
• Yellow Fever 
• Zika 
• Other (Emerging Infections) 
Diseases Associated with Person-to-Person Contact: 
• Diphtheria 
• Hepatitis B 
• Hepatitis C 
• Influenza 
64 
 
• Measles 
• Meningococcal disease 
• Mumps 
• Pertussis 
• Pneumococcal disease 
• Rubella 
• Sexually transmitted diseases 
• Tuberculosis 
• Varicella 
• Other 
Diseases Associated with Ingestion of Food and Water: 
• Amebiasis 
• Brucellosis 
• Cholera 
• Cryptosporidiosis 
• Cyclosporiasis 
• Giardiasis 
• Hepatitis A 
• Hepatitis E 
• Norovirus 
• Poliomyelitis 
• Seafood poisoning/toxins 
• Travellers’ diarrhea 
• Typhoid and paratyphoid fever 
• Other 
Diseases Associated with Bites and Stings: 
• Envenomation (e.g., jelly fish, sea urchin, scorpion, snake, spiders) 
• Herpes B virus 
• Rabies 
• Others 
Diseases Associated with Water/Environmental Contact: 
• Cutaneous larva migrans 
• Legionella 
• Leptospirosis 
• Schistosomiasis 
• Tetanus 
• Other 
5. Other Clinical Conditions Associated with Travel (10%) 
Conditions Occurring During or Immediately Following Travel. Symptoms prevention, and 
treatment of: 
• Barotrauma 
• Jet Lag 
• Motion sickness 
• Thrombosis/embolism 
• Other 
Conditions Associated with Environmental Factors. Symptoms, prevention, and treatment 
of: 
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• Altitude sickness 
• Frostbite and hypothermia 
• Respiratory distress/failure (associated with humidity, pollution, etc.) 
• Sunburn, heat exhaustion, and sun stroke 
• Other 
Threats to Personal Security. Precautions regarding: 
• Accidents (e.g., motor vehicle, drowning) 
• Violence-related injuries 
• Other 
Psychological and Psycho-social Issues. Unique management issues associated with: 
• Acute stress reactions, post-traumatic stress disorder 
• Culture shock/adaptation (e.g., travellers, refugees) 
• Psychiatric and psychological sequelae of travel or living abroad 
• Other (e.g., flight phobia) 
6. Post-Travel Assessment (8%) 
Screening/assessment of returned asymptomatic travelers 
Screening/assessment of immigrants 
Triage of the ill traveler 
Diagnostic and management implications of the following symptoms: 
• Diarrhea and other gastro-intestinal complaints 
• Eosinophilia 
• Fever 
• Respiratory Illness 
• Skin problems 
• Other 
7. Administrative and General Travel Medicine Issues (5%) 
Medical Care Abroad: 
• Aeromedical evacuation (including repatriation of deceased) 
• Blood transfusion guidelines for international travellers 
• Procedures and considerations regarding medical and mental health care and 
recommendations regarding access of medications in resource-poor areas 
• Other 
Travel Clinical Management: 
• Documentation and record-keeping (e.g., vaccination certificate requirements, 
reporting of adverse events) 
• Equipment 
• Infection control procedures 
• Management of medical emergencies 
• Resources for laboratory testing 
• Supplies and disposables including medications 
• Other 
Travel Medicine Information/Resources: 
• Accessing health information including commercial and proprietary sources 
• International Health Regulations 
• National/regional recommendations, including national/regional differences 
• Principles of responsible travel 
• Other 
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Appendix B – Pre-Test Survey Questions 
 
Question Answer Options 
Screening 
Do you currently work in a 
community pharmacy practice 
setting? 
• Yes 
• No 
Do you currently have an Ontario 
Part A license to practice pharmacy 
in the province? 
• Yes 
• No 
Do you currently have the Certificate 
in Travel HealthTM from the 
International Society of Travel 
Medicine? 
• Yes 
• No 
Demographics 
Which type of community pharmacy 
practice setting do you primarily 
work in? 
• Independent community pharmacy 
• Community pharmacy associated with 
a chain 
• Community pharmacy associated with 
a banner 
• Community pharmacy associated with 
a grocery store 
• Community pharmacy associated with 
a mass merchandiser 
• Other (please specify) 
What is your role in the community 
pharmacy practice setting you work 
in? 
• Community pharmacy owner 
• Community pharmacy staff pharmacist 
• Community pharmacy relief 
pharmacist 
Are you the pharmacy’s designated 
manager? 
• Yes 
• No 
Where is your community pharmacy 
practice setting located? 
• Central East 
• Central South 
• Central West 
• East 
• North 
• South West 
• Toronto 
How many years have you worked in 
a community pharmacy practice 
setting? 
• Currently on a community pharmacy 
rotation 
• Less than 1 
• 1-5 
• 6-10 
• 11-20 
• 21-30 
• More than 30 
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On average, how many hours per 
week do you work in a community 
pharmacy practice setting? 
• Currently on a community pharmacy 
rotation 
• Less than 8 
• 8-16 
• 17-24 
• 25-32 
• 33-40 
• More than 40 
Which gender do you most identify 
with? 
• Male 
• Female 
• Gender variant/non-conforming 
Are you authorized to administer 
injections in Ontario? 
• Yes 
• No 
What degrees/training have you 
received? Select all that apply. 
• Currently on clinical rotations for 
entry-to-practice PharmD 
• BSc Pharmacy 
• Post-baccalaureate PharmD 
• Entry-to-practice PharmD 
• Masters in Pharmacy 
• PhD in Pharmacy 
• Residency 
• Fellowship 
• Other (please specify) 
Which of the following travel or 
travel-related vaccines have you 
personally administered since the 
expansion of Ontario pharmacists’ 
scope in December 2016? Select all 
that apply. 
• Bacille Calmette-Guerin (BCG) (for 
tuberculosis) 
• Haemophilus influenza type B 
• Hepatitis A 
• Hepatitis B 
• Combined hepatitis A and B 
• Herpes zoster (shingles) 
• Human papillomavirus (HPV) 
• Japanese encephalitis 
• Meningitis 
• Pneumococcus 
• Rabies 
• Typhoid 
• Combined typhoid and hepatitis A 
• Varicella zoster (chickenpox) 
• Yellow Fever 
• None of the above 
Does your pharmacy currently offer 
travel health services other than 
administration of travel vaccines 
(e.g. pretravel consultations)? 
• Yes 
• No 
Pharmacy Practice 
What do you do when a patient 
presents to the pharmacy 
wondering what precautions they 
• Refer all patients to a travel clinic or to 
their physician 
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need for upcoming their travel 
destination? Select all that apply. 
 
• Provide information on general 
precautions 
• Refer them to online or paper resources 
• Perform a complete consultation for 
less complex patients only (e.g. all-
inclusive resort in the Caribbean, 
cruise) and refer all others 
• Other (please specify) 
Please describe your current 
willingness to incorporate travel 
medicine services at your 
pharmacy. 
Free-text response 
Please describe the primary barrier(s) 
preventing your pharmacy from 
starting travel medicine services 
Free-text response 
Please describe the primary 
motivator(s) for your pharmacy 
wanting to start travel medicine 
services 
Free-text response 
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Appendix C - Post-Test Survey Questions 
Question Answer Options 
Practice Questions 
What do you do when a patient presents 
to the pharmacy wondering what 
precautions they need for upcoming 
their travel destination? Select all that 
apply. 
 
• Refer all patients to a travel clinic or 
to their physician 
• Provide information on general 
precautions 
• Refer them to online or paper 
resources 
• Perform a complete consultation for 
less complex patients only (e.g. all-
inclusive resort in the Caribbean, 
cruise) and refer all others 
• Other (please specify) 
Please describe your current willingness 
to incorporate travel medicine services 
at your pharmacy. 
 
Free-text response 
Please describe the primary barrier(s) 
preventing your pharmacy from 
starting travel medicine services. 
 
Free-text response 
Please describe the primary motivator(s) 
for your pharmacy wanting to start 
travel medicine services. 
 
Free-text response 
When and how do you currently offer 
travel consultations at your pharmacy? 
Select all that apply. 
• Anytime by walk-in 
• During set days/hours by walk-in 
(e.g. clinic days) 
• By appointment 
• Other (please specify) 
Does your pharmacy charge a fee to 
patients for a travel consultation? 
 
• Yes (please specify the fee amount) 
• No 
Framework 
Please describe the main advantages of 
the framework. 
 
Free-text response 
Please describe the main disadvantages 
of the framework. 
 
Free-text response 
Please provide any suggestions, 
improvements, or clarifications 
needed for future editions of the 
framework 
Free-text response 
Appendix D -Summary of Item Results from Content Judgement Phase 
Domain: Who? Essential 
(%, n) 
Useful, but not 
essential 
Not 
necessary 
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(%, n) (%, n) 
Health Conditions    
Diabetes* 66.7% (6) 11.1% (1) 0% (0) 
High blood pressure 11.1% (1) 55.6% (5) 11.1% (1) 
High cholesterol 0% (0) 66.7% (6) 11.1% (1) 
Blood or clotting disorder* 77.8% (7) 0% (0) 0% (0) 
Heart disease or arrhythmia* 66.7% (6) 11.1% (1) 0% (0) 
Seizure disorder* 66.7% (6) 11.1% (1) 0% (0) 
Emotional/psychiatric 
condition(s) * 
77.8% (7) 0% (0) 0% (0) 
Lung condition (Asthma/COPD) 44.4% (4) 33.3% (3) 0% (0) 
Migraines or headaches 0% (0) 66.7% (6) 11.1% (1) 
Irritable Bowel Syndrome or 
digestive tract problems 
22.2% (2) 44.4% (4) 11.1% (1) 
Inflammatory Bowel Disease* 55.6% (5) 22.2% (2) 0% (0) 
Acid Reflux or heartburn 33.3% (3) 44.4% (4) 0% (0) 
Thymus disorders (e.g. 
myasthenia gravis) * 
66.7% (6) 11.1% (1) 0% (0) 
Radical mastectomy or lymph-
node dissection 
44.4% (4) 33.3% (3) 0% (0) 
Liver or kidney disease* 77.8% (7) 0% (0) 0% (0) 
Damaged or removed spleen* 77.8% (7) 0% (0) 0% (0) 
Organ or bone marrow 
transplant* 
77.8% (7) 0% (0) 0% (0) 
Recent chemotherapy or radiation 
(4 months) * 
77.8% (7) 0% (0) 0% (0) 
HIV, AIDS, immune suppressed 
or immunocompromised* 
77.8% (7) 0% (0) 0% (0) 
Psoriasis 44.4% (4) 33.3% (3) 0% (0) 
Ear/hearing problems 0% (0) 77.8% (7) 0% (0) 
Anemia 11.1% (1) 66.7% (6) 0% (0) 
Considerations for Females when Traveling 
Currently pregnant* 77.8% (7) 0% (0) 0% (0) 
Planning to get pregnant soon 
after travel* 
77.8% (7) 0% (0) 0% (0) 
Breastfeeding* 55.6% (5) 22.2% (2) 0% (0) 
Date of last menstrual period 22.2% (2) 33.3% (3) 22.2% (2) 
Demographics 
Age* 77.8% (7) 0% (0) 0% (0) 
Date of birth (for immunization 
purposes) * 
55.6% (5) 22.2% (2) 0% (0) 
Medications 
Blood thinners (e.g. warfarin, 
clopidogrel) * 
77.8% (7) 0% (0) 0% (0) 
Corticosteroids* 66.7% (6) 11.1% (1) 0% (0) 
Chemotherapy or other anti-
cancer medications* 
77.8% (7) 0% (0) 0% (0) 
Quinine, quinidine, or other 
cardiac drugs* 
66.7% (6) 11.1% (1) 0% (0) 
Antibiotics 33.3% (3) 44.4% (4) 0% (0) 
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Medication for mood disorders or 
emotional problems* 
55.6% (5) 22.2% (2) 0% (0) 
Medications to control seizures* 55.6% (5) 22.2% (2) 0% (0) 
Other prescription medications 33.3% (3) 44.4% (4) 0% (0) 
Allergy 
Sulfa drugs 22.2% (2) 55.6% (5) 0% (0) 
Streptomycin, gentamicin or 
neomycin* 
55.6% (5) 22.2% (2) 0% (0) 
Penicillin 22.2% (2) 55.6% (5) 0% (0) 
Latex 44.4% (4) 33.3% (3) 0% (0) 
Yeast 44.4% (4) 33.3% (3) 0% (0) 
Gelatin 33.3% (3) 44.4% (4) 0% (0) 
Eggs or other foods 44.4% (4) 33.3% (3) 0% (0) 
Adhesive bandages 16.7% (1) 83.3% (5) 0% (0) 
Travel Companion 
Alone 33.3% (3) 44.4% (4) 0% (0) 
With spouse/partner 0% (0) 66.7% (6) 11.1% (1) 
With a group 0% (0) 66.7% (6) 11.1% (1) 
With children* 55.6% (5) 22.2% (2) 0% (0) 
With an older/elderly person 57.4% (4) 33.3% (3) 0% (0) 
Immunization History 
In what country were you born? 44.4% (4) 33.3% (3) 0% (0) 
If you were not born in Canada, 
at what age did you leave your 
country of birth?† 
55.6% (5) 22.2% (2) 0% (0) 
Determining if the patient is 
aware of their immunization 
status* 
77.8% (7) 0% (0) 0% (0) 
Has fainted or felt unwell after an 
injection 
33.3% (3) 33.3% (3) 11.1% (1) 
Had a serious reaction in the past 
with vaccines* 
77.8% (7) 0% (0) 0% (0) 
Had (or currently has) a fear of 
needles 
33.3% (3) 44.4% (4) 0% (0) 
Carries an Epi-Pen 33.3% (3) 33.3% (3) 11.1% (1) 
Domain: Where? Essential 
(%, n) 
Useful, but not 
essential 
(%, n) 
Not 
necessary 
(%, n) 
Destination(s) 
Country/Countries* 77.8% (7) 0% (0) 0% (0) 
Cities/Regions* 66.7% (6) 11.1% (1) 0% (0) 
Dates of travel for each country 
and/or city (if more than one)* 
77.8% (7) 0% (0) 0% (0) 
Rural/urban areas* 77.8% (7) 0% (0) 0% (0) 
Accommodations 
Premium hotel 44.4% (4) 22.2% (2) 11.1% (1) 
Budget hotel 44.4% (4) 33.3% (3) 0% (0) 
Resort 33.3% (3) 44.4% (4) 0% (0) 
Cruise 44.4% (4) 33.3% (3) 0% (0) 
Hostel* 55.6% (5) 22.2% (2) 0% (0) 
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Friends/family's home* 77.8% (7) 0% (0) 0% (0) 
Camping* 55.6% (5) 22.2% (2) 0% (0) 
Dining 
Local restaurants/bars 33.3% (3) 44.4% (4) 0% (0) 
Cooking themselves 33.3% (3) 44.4% (4) 0% (0) 
Friend/family cooking* 55.6% (5) 22.2% (2) 0% (0) 
Street food and vendors* 55.6% (5) 22.2% (2) 0% (0) 
Domain: When? Essential 
(%, n) 
Useful, but not 
essential 
(%, n) 
Not 
necessary 
(%, n) 
Timing    
Departure/Arrival Dates* 55.6% (5) 22.2% (2) 0% (0) 
Last minute traveler (<4 weeks 
before departure date)* 
77.8% (7) 0% (0) 0% (0) 
Time of year 44.4% (4) 33.3% (3) 0% (0) 
Length of stay* 66.7% (6) 11.1% (1) 0% (0) 
Domain: Why? Essential 
(%, n) 
Useful, but not 
essential 
(%, n) 
Not 
necessary 
(%, n) 
Reason(s) for Travel    
Visiting friends/family* 77.8% (7) 0% (0) 0% (0) 
Business 33.3% (3) 44.4% (4) 0% (0) 
Athletic competition* 55.6% (5) 22.2% (2) 0% (0) 
Religion (e.g. Hajj)* 66.7% (6) 11.1% (1) 0% (0) 
Medical tourism* 77.8% (7) 0% (0) 0% (0) 
Sexual tourism* 77.8% (7) 0% (0) 0% (0) 
Humanitarian work* 77.8% (7) 0% (0) 0% (0) 
Vacation 44.4% (4) 33.3% (3) 0% (0) 
Adventure* 66.7% (6) 11.1% (1) 0% (0) 
Research/Education* 55.6% (5) 22.2% (2) 0% (0) 
Adoption* 55.6% (5) 22.2% (2) 0% (0) 
Domain: What? Essential 
(%, n) 
Useful, but not 
essential 
(%, n) 
Not 
necessary 
(%, n) 
Planned Activities    
Scuba diving* 66.7% (6) 11.1% (1) 0% (0) 
Going to high altitude* 77.8% (7) 0% (0) 0% (0) 
Safari* 55.6% (5) 22.2% (2) 0% (0) 
Spending time in rural 
communities or remote areas* 
66.7% (6) 11.1% (1) 0% (0) 
Adventure travel* 55.6% (5) 22.2% (2) 0% (0) 
Close contact with animals* 77.8% (7) 0% (0) 0% (0) 
Providing medical care* 77.8% (7) 0% (0) 0% (0) 
Exposure to extreme heat or 
cold* 
66.7% (6) 11.1% (1) 0% (0) 
Jungle* 66.7% (6) 11.1% (1) 0% (0) 
Cave exploration* 66.7% (6) 11.1% (1) 0% (0) 
Hiking or trekking* 66.7% (6) 11.1% (1) 0% (0) 
Rafting or kayaking* 66.7% (6) 11.1% (1) 0% (0) 
Restricted work camp* 66.7% (6) 11.1% (1) 0% (0) 
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Misc. excursion off resort 44.4% (4) 33.3% (3) 0% (0) 
Transportation 
Train 11.1% (1) 66.7% (6) 0% (0) 
Rental car 22.2% (2) 55.6% (5) 0% (0) 
In-country flights 11.1% (1) 66.7% (6) 0% (0) 
Boat 44.4% (4) 33.3% (3) 0% (0) 
Motorcycle* 55.6% (5) 22.2% (2) 0% (0) 
Type of Travel 
Package 22.2% (2) 44.4% (4) 11.1% (1) 
Camping 33.3% (3) 44.4% (4) 0% (0) 
Self-organized 22.2% (2) 44.4% (4) 11.1% (1) 
Cruise ship 33.3% (3) 44.4% (4) 0% (0) 
Backpacking* 55.6% (5) 22.2% (2) 0% (0) 
Trekking* 55.6% (5) 22.2% (2) 0% (0) 
Domain: How? Essential 
(%, n) 
Useful, but not 
essential 
(%, n) 
Not 
necessary 
(%, n) 
Travel Experience 
New traveller 33.3% (3) 44.4% (4) 0% (0) 
Local trips only, never overseas 22.2% (2) 55.6% (5) 0% (0) 
Travelled overseas 22.2% (2) 55.6% (5) 0% (0) 
Experienced traveller 22.2% (2) 55.6% (5) 0% (0) 
* Item considered ‘essential’ and included in stage 3.  
† Not included in stage 3, as it was a follow-up question to “In what country were 
you born?” 
